Search PDMR transactions

Notifier
Name of person with notification obligation
Liljeblad & Co Aktiebolag
Reason for notification
Closely associated
Yes
Person discharging managerial responsibilities
Anders Liljeblad
Position
Chief Executive Officer (CEO)/Managing Directory
Initial notification
Yes
Amendment
No
Details of amendment
Details of the Issuer/emission allowance market participant/auction platform/auctioneer/auction monitor
Name of issuer
Prostatype Genomics AB
Issuer´s LEI code
549300JO6MPCGPVHVU91
Details of transaction
Type of financial instrument Financial instrument ISIN code Nature of transaction Linked to the exercise of a share option programme Volume Unit Price per unit Currency code Transaction date Place of the transaction
Share Prostatype Genomics AB stamaktie SE0023261532 Acquisition 5,750,000 Quantity 0.10 SEK 31/08/2026 Outside a trading venue
Subcription warrant Prostatype Genomics AB TO6 SE0029529767 Acquisition 1,437,500 Quantity 0.00 SEK 31/08/2026 Outside a trading venue
Subcription warrant Prostatype Genomics AB TO7 SE0029529783 Acquisition 2,875,000 Quantity 0.00 SEK 31/08/2026 Outside a trading venue
Aggregation
Financial instrument ISIN code Nature of transaction Transaction date Place of the transaction Volume Weighted average price
Prostatype Genomics AB stamaktie SE0023261532 Acquisition 31/08/2026 Outside a trading venue 5,750,000 (Quantity) 0.10 SEK
Prostatype Genomics AB TO6 SE0029529767 Acquisition 31/08/2026 Outside a trading venue 1,437,500 (Quantity) 0.00 SEK
Prostatype Genomics AB TO7 SE0029529783 Acquisition 31/08/2026 Outside a trading venue 2,875,000 (Quantity) 0.00 SEK
<< Back